Physician profile
Sumit Bhandari
NPI 1336452572
$571.64
in general payments reported to CMS, 2019-2025
11 companies · $97.21 in 2025
The $97.21 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $94.91 · 2021: $32.96 · 2022: $74.14 · 2023: $102 · 2024: $14.14 · 2025: $97.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $213.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $194.15 | 2019-2023 | |
| Abbvie INC. | $98.38 | 2021-2025 | |
| Gilead Sciences, INC. | $52.56 | 2023-2025 | Veklury |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.06 | 2019-2022 | |
| Pfizer INC. | $35.71 | 2020-2025 | |
| Allergan, INC. | $34.68 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.52 | 2020-2024 | Xarelto |
| Melinta Therapeutics, LLC | $27.30 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.43 | 2023 | Ultomiris |
| Janssen Biotech, INC. | $14.68 | 2025 | Tremfya |
| Astrazeneca Pharmaceuticals Lp | $14.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.